MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 74 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.59 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $144,000 | +3.6% | 56,707 | -17.2% | 0.00% | – |
| Q1 2020 | $139,000 | -27.2% | 68,496 | -22.2% | 0.00% | – |
| Q4 2019 | $191,000 | +85.4% | 88,089 | +32.2% | 0.00% | – |
| Q3 2019 | $103,000 | -67.6% | 66,626 | -13.2% | 0.00% | – |
| Q2 2019 | $318,000 | +4.3% | 76,732 | +5.3% | 0.00% | – |
| Q1 2019 | $305,000 | +24.0% | 72,857 | -14.9% | 0.00% | – |
| Q4 2018 | $246,000 | -71.2% | 85,663 | +0.4% | 0.00% | – |
| Q3 2018 | $853,000 | +54.2% | 85,315 | +9.0% | 0.00% | – |
| Q2 2018 | $553,000 | – | 78,276 | +602023.1% | 0.00% | – |
| Q4 2017 | $0 | -100.0% | 13 | -99.5% | 0.00% | – |
| Q2 2017 | $4,000 | -78.9% | 2,617 | -75.5% | 0.00% | – |
| Q1 2017 | $19,000 | -5.0% | 10,693 | -45.5% | 0.00% | – |
| Q4 2016 | $20,000 | -54.5% | 19,623 | -18.0% | 0.00% | – |
| Q3 2016 | $44,000 | +83.3% | 23,925 | +24.3% | 0.00% | – |
| Q2 2016 | $24,000 | -78.8% | 19,251 | -8.8% | 0.00% | – |
| Q1 2016 | $113,000 | +189.7% | 21,100 | +308.9% | 0.00% | – |
| Q4 2015 | $39,000 | +680.0% | 5,160 | +695.1% | 0.00% | – |
| Q3 2015 | $5,000 | -37.5% | 649 | -10.1% | 0.00% | – |
| Q2 2015 | $8,000 | – | 722 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 1,192,883 | $15,329,000 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 1,431,059 | $18,389,000 | 1.71% |
| Avoro Capital Advisors LLC | 3,000,000 | $38,550,000 | 0.55% |
| Palo Alto Investors LP | 31,330 | $403,000 | 0.02% |